Some stakeholders argued that exclusivity agreements between drug manufacturers and distributors can artificially inflate prices and limit consumers’ access to medication choice. For example, some retail outlets report difficulties ensuring they have brand medications available for customers, and some veterinarians report difficulties ensuring generic medications are available at their clinics. Others reported that consumers are not being sufficiently informed of the options available to them when purchasing pet medications, including the option of receiving a written copy of their pet’s prescriptions from their veterinarian.  - Frank Pallone Jr. DEM NJ